|
|
Profile
|
Delegates :
President & CEO Kensuke Tomita |
|
Incorporated :
August 24 , 2004 |
Paid in Capital :
340 Million yen |
Employees :
6 人 |
Address :
KSP R&D C6F 3-2-1 Sakado, Takatsu-ku, Kawasaki, KANAGAWA
〒213-0012
|
TEL/FAX :
+81-44-820-8251 / +81-44-820-8252 |
URL：
none |
Attachment :
|
Mission/Background :
Immunas is a bio-venture company specialized in generation of antibody medicines against to disease-specific molecule. Our developmental area is cancer and Alzheimer’s disease, and our primary aim is to provide the patients with these diseases with antibody medicines which perform clear-cut efficacy while minimizing adverse effects as soon as possible. |
|
Technology & Business
|
Immunas has developed the antibody medicine against to amyloid beta oligomers (Abeta oligomers) which is believed as pathogenic factor in Alzheimer’s disease for several years. We are succeeded to obtain a number of antibodies bound to the Abeta oligomer, and continue the research to develop them as the therapeutic medicine.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Anti Abeta oligomer Antibody
|
Discovery
|
therapeutic medicine for Alzheimer’s disease
|
allaiance
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We are succeeded to obtain over 180 anti-Abeta oligomers antibodies, and their patent application has been completed. Recently, we selected a lead antibody as the candidate for the clinical development. The selected antibody showed high specificity, high affinity and strong efficacy in pharmacological experiment. Furthermore we confirmed non-binding profile of this antibody to the normal human tissue array, suggesting that we can minimize adverse effects of this antibody in clinical trial.
|
|
Alliance strategy
|
We are looking for business partners to develop therapeutic medicine and diagnosis of Alzheimer’s disease using anti-Amyloid beta oligomers antibodies.
|
|
|